Golimumab for rheumatoid arthritis: A systematic review

Journal of Rheumatology

Volumn 37, Issue 6, 2010, Pages 1096-1104

  Singh, Jasvinder A ^a,b   Noorbaloochi, Shahrzad ^b   Singh, Gurkirpal ^c  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^b Mayo Clinic   (United States)

^c STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Efficacy; Golimumab; Rheumatoid arthritis; Safety; Systematic review

Indexed keywords

DISEASE MODIFYING ANTIRHEUMATIC DRUG; GOLIMUMAB; METHOTREXATE; PLACEBO;

CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DATA BASE; DEATH; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; FOOD AND DRUG ADMINISTRATION; HEALTH ASSESSMENT QUESTIONNAIRE; HUMAN; INFECTION; LUNG INFECTION; NEOPLASM; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REVIEW; RHEUMATOID ARTHRITIS; SYSTEMATIC REVIEW; TUBERCULOSIS; UNSPECIFIED SIDE EFFECT;

ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; DRUG THERAPY, COMBINATION; HEALTH STATUS; HUMANS; METHOTREXATE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECOVERY OF FUNCTION; REMISSION INDUCTION; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 77953185417     PISSN: 0315162X     EISSN: None     Source Type: Journal    
DOI: 10.3899/jrheum.091466     Document Type: Review

References (49)

1. Lee DM, Weinblatt ME. Rheumatoid arthritis. Lancet 2001;358:903-911
2. Kvien TK, Uhlig T. Quality of life in rheumatoid arthritis. Scand J Rheumatol 2005;34:333-341
3. Lubeck DP. Patient-reported outcomes and their role in the assessment of rheumatoid arthritis. Pharmacoeconomics 2004;22(2 Suppl 1):27-38.
4. Odegard S, Finset A, Kvien TK, Mowinckel P, Uhlig T. Work disability in rheumatoid arthritis is predicted by physical and psychological health status: a 7-year study from the Oslo RA register. Scand J Rheumatol 2005;34:441-447
5. Yelin E. Work disability in rheumatic diseases. Curr Opin Rheumatol 2007;19:91-96
6. Weissmann G. The pathogenesis of rheumatoid arthritis. Bull NYU Hosp Jt Dis 2006;64:12-15
7. Choy EH, Panayi GS. Cytokine pathways and joint inflammation in rheumatoid arthritis. N Engl J Med 2001;344:907-916
8. Brennan FM, McInnes IB. Evidence that cytokines play a role in rheumatoid arthritis. J Clin Invest 2008;118:3537-3545
9. Connell L, McInnes IB. New cytokine targets in inflammatory rheumatic diseases. Best Pract Res Clin Rheumatol 2006;20:865-878
10. Scott DL, Kingsley GH. Tumor necrosis factor inhibitors for rheumatoid arthritis. N Engl J Med 2006;355:704-712
11. Blumenauer B, Cranney A, Burls A, Coyle D, Hochberg M, Tugwell P, et al. Etanercept for the treatment of rheumatoid arthritis. Cochrane Database Syst Rev 2003:CD004525.
12. Blumenauer B, Judd M, Wells G, Burls A, Cranney A, Hochberg M, et al. Infliximab for the treatment of rheumatoid arthritis. Cochrane Database Syst Rev 2002:CD003785.
13. Navarro-Sarabia F, Ariza-Ariza R, Hernandez-Cruz B, Villanueva I. [Adalimumab for treating rheumatoid arthritis]. Cochrane Database Syst Rev 2005:CD005113.
14. Mertens M, Singh JA. Anakinra for rheumatoid arthritis: a systematic review. J Rheumatol 2009;36:1118-1125
15. Maxwell L, Singh JA. Abatacept for rheumatoid arthritis. Cochrane Database Syst Rev 2009:CD007277.
16. Siddiqui MA. The efficacy and tolerability of newer biologics in rheumatoid arthritis: best current evidence. Curr Opin Rheumatol 2007;19:308-313
17. US Food and Drug Administration. Simponi® (golimumab) physician packet insert: highlights of prescribing information, 2009. [Internet. Accessed March 15, 2010.] Available from: http://www.accessdata.fda.gov/drugsatfda-docs/ label/2009/125289s000lbl.pdf
18. US Food and Drug Administration. Simponi® (golimumab) summary review. FDA Center for Drug Evaluation and Research, 2009. [Internet. Accessed Sept 20, 2009.] Available from: http://www.accessdata.fda.gov/drugsatfda-docs/nda/2009/ 125289s000-SumR.pdf
19. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988;31:315-324
20. Fries JF, Spitz P, Kraines RG, Holman HR. Measurement of patient outcome in arthritis. Arthritis Rheum 1980;23:137-145
21. Pincus T, Chung C, Segurado OG, Amara I, Koch GG. An index of patient reported outcomes (PRO-Index) discriminates effectively between active and control treatment in 4 clinical trials of adalimumab in rheumatoid arthritis. J Rheumatol 2006;33:2146-2152 (Pubitemid 44749771)
22. Wells GA, Tugwell P, Kraag GR, Baker PR, Groh J, Redelmeier DA. Minimum important difference between patients with rheumatoid arthritis: the patient's perspective. J Rheumatol 1993;20:557-560 (Pubitemid 23102493)
23. Chung CP, Thompson JL, Koch GG, Amara I, Strand V, Pincus T. Are American College of Rheumatology 50% response criteria superior to 20% criteria in distinguishing active aggressive treatment in rheumatoid arthritis clinical trials reported since 1997? A meta-analysis of discriminant capacities. Ann Rheum Dis 2006;65:1602-1607
24. Felson DT, Anderson JJ, Boers M, Bombardier C, Furst D, Goldsmith C, et al. American College of Rheumatology. Preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum 1995;38:727-735
25. van der Heijde DM, van't Hof M, van Riel PL, van de Putte LB. Development of a disease activity score based on judgment in clinical practice by rheumatologists. J Rheumatol 1993;20:579-581
26. Prevoo ML, van't Hof MA, Kuper HH, van Leeuwen MA, van de Putte LB, van Riel PL. Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum 1995;38:44-48
27. Fransen J, van Riel PL. The Disease Activity Score and the EULAR response criteria. Clin Exp Rheumatol 2005;23(5 Suppl 39):S93-9.
28. van Gestel AM, Prevoo ML, van't Hof MA, van Rijswijk MH, van de Putte LB, van Riel PL. Development and validation of the European League Against Rheumatism response criteria for rheumatoid arthritis. Comparison with the preliminary American College of Rheumatology and the World Health Organization/International League Against Rheumatism Criteria. Arthritis Rheum 1996;39:34-40.
29. Larsen A, Dale K, Eek M. Radiographic evaluation of rheumatoid arthritis and related conditions by standard reference films. Acta Radiol Diagn 1977;18:481-491 (Pubitemid 8198049)
30. Sharp JT, Lidsky MD, Collins LC, Moreland J. Methods of scoring the progression of radiologic changes in rheumatoid arthritis. Correlation of radiologic, clinical and laboratory abnormalities. Arthritis Rheum 1971;14:706-720
31. van der Heijde DM, van Riel PL, Nuver-Zwart IH, Gribnau FW, van de Putte LB. Effects of hydroxychloroquine and sulphasalazine on progression of joint damage in rheumatoid arthritis. Lancet 1989;1:1036-1038 (Pubitemid 19123055)
32. Higgins JP, Altman DG. Assessing risk of bias in included studies. Cochrane handbook for systematic reviews of interventions, version 5.0.0 (updated February 2008). In: www.cochrane-handbook.org: The Cochrane Collaboration; 2008.
33. Atkins D, Eccles M, Flottorp S, Guyatt GH, Henry D, Hill S, et al. Systems for grading the quality of evidence and the strength of recommendations I: critical appraisal of existing approaches. The GRADE Working Group. BMC Health Serv Res 2004;4:38.
34. Deeks J, Higgins J, Altman D. Analysing data and undertaking meta-analyses, Cochrane handbook for systematic reviews of interventions version 5.0.0 (updated February 2008). In: www.cochrane-handbook.org: The Cochrane Collaboration; 2008.
35. Cates C. Dr. Chris Cates' EBM Web Site. Visual Rx Version 3. [Internet. Accessed Feb 13, 2009.] Available from: http://www.nntonline.net/visualrx/
36. Keystone EC, Genovese MC, Klareskog L, Hsia EC, Hall ST, Miranda PC, et al. Golimumab, a human antibody to tumour necrosis factor (alpha) given by monthly subcutaneous injections, in active rheumatoid arthritis despite methotrexate therapy: the GO-FORWARD Study. Ann Rheum Dis 2009;68:789-796
37. Kay J, Matteson EL, Dasgupta B, Nash P, Durez P, Hall S, et al. Golimumab in patients with active rheumatoid arthritis despite treatment with methotrexate: a randomized, double-blind, placebo-controlled, dose-ranging study. Arthritis Rheum 2008;58:964-975
38. Smolen JS, Kay J, Doyle MK, Landewe R, Matteson EL, Wollenhaupt J, et al. Golimumab in patients with active rheumatoid arthritis after treatment with tumour necrosis factor alpha inhibitors (GO-AFTER study): a multicentre, randomised, double-blind, placebo-controlled, phase III trial. Lancet 2009;374:210-221
39. Emery P, Fleischmann RM, Moreland LW, Hsia EC, Strusberg I, Durez P, et al. Golimumab, a human anti-tumor necrosis factor alpha monoclonal antibody, injected subcutaneously every four weeks in methotrexate-naive patients with active rheumatoid arthritis: twenty-four-week results of a phase III, multicenter, randomized, double-blind, placebo-controlled study of golimumab before methotrexate as first-line therapy for early-onset rheumatoid arthritis. Arthritis Rheum 2009;60:2272-2283
40. Singh JA, Noorbaloochi S, Singh G. Golimumab for rheumatoid arthritis. Cochrane Database Syst Rev 2010;CD008341.
41. Lopez-Olivo M, Amezaga M, McGahan L, Suarez-Almazor M. Rituximab for rheumatoid arthritis. Cochrane Database Syst Rev 2008;CD007356.
42. Gomez-Reino JJ, Carmona L. Switching TNF antagonists in patients with chronic arthritis: an observational study of 488 patients over a four-year period. Arthritis Res Ther 2006;8:R29.
43. Karlsson JA, Kristensen LE, Kapetanovic MC, Gulfe A, Saxne T, Geborek P. Treatment response to a second or third TNF-inhibitor in RA: results from the South Swedish Arthritis Treatment Group Register. Rheumatology 2008;47:507-513
44. Blumenauer B, Judd M, Cranney A, Burls A, Coyle D, Hochberg M, et al. Etanercept for the treatment of rheumatoid arthritis. Cochrane Database Syst Rev 2003:CD004525.
45. Lopez-Olivo M, Amezaga M, McGahan L, Suarez-Almazor M. Rituximab for rheumatoid arthritis. Cochrane Database Syst Rev 2008:CD007356.
46. Yazici Y. Treatment of rheumatoid arthritis: we are getting there. Lancet 2009;374:178-180
47. Pappas DA, Bathon JM, Hanicq D, Yasothan U, Kirkpatrick P. Golimumab. Nat Rev Drug Discov 2009;8:695-696
48. Oldfield V, Plosker GL. Golimumab: in the treatment of rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis. BioDrugs 2009;23:125-135
49. Hutas G. Golimumab, a fully human monoclonal antibody against TNF alpha. Curr Opin Mol Ther 2008;10:393-406.